Polycythemia vera (PV) is a chronic myeloproliferative disorder (MPD) characterized by an excess production of apparently normal erythrocytes and a variable overproduction of leukocytes and platelets in the absence of a defined cause. Recent PV studies have identified in several patients an acquired valine-tophenylalanine mutation at amino acid 617 (V617F) in the Janus kinase 2 (JAK2) tyrosine kinase gene. This mutation, however, is not present in all PV patients. 1, 2 Other studies have reported a number of gene fusions resulting from chromosomal aberrations, but no recurrent chromosomal abnormality has been identified so far.
We report here a PV case showing a novel, balanced t(3;12)(q26;q14) translocation, involving the 3 0 UTR of the gene HMGA2 (high mobility group AT-hook 2 isoform a) and the coding region of the TNIK (Traf2-and Nck-interacting kinase). Molecular analyses demonstrated an overexpression of HMGA2, which, however, was not due to the formation of a fusion transcript with TNIK, but, very likely, to a position effect. TNIK expression pattern was not affected by the rearrangement.
A 68-year-old man presented in February 2002 with polycythemia, and a 60% hematocrit (Hct) level. Bone marrow trephine biopsy showed a hypercellular marrow with an increased erythroid series. Molecular analysis revealed homozygosity for JAK2 V617F . In accordance with polycythemia vera study group (PVSG) criteria, a diagnosis of PV was made. The patient was treated with phlebotomy, performed every 2-3 months, and hydroxyurea. To date, he is alive and periodically undergoes phlebotomy.
Bone marrow (BM) karyotype revealed a translocation 46,XY,t(3;12)(q26;q14) [11] (Figure 1a ). Multicolor-fluorescent in situ hybridization (FISH), performed using the commercially available 24-colour SpectraVysion probe (Abbott, Abbott Park IL, USA), confirmed the t(3;12) rearrangement ( Figure 1a) . FISH experiments using appropriate BAC clones, identified in the UCSC database (www.genome.ucsc.edu/March 2006 release), revealed that the breakpoints were located within BAC clones RP11-466C5 (chr3:172 251 934-172 458 321, at 3q26.2; Figure  1a and b), and RP11-366L20 (chr12:64 532 786-64 711 531, at 12q14.3; Figure 1a and b). The sequence encompassed by the latter BAC was found to contain only the gene HMGA2. The breakpoint region on chromosome 3 was also found to contain a single gene, TNIK, encoding a stress-activated serine/threonine kinase. To further narrow the breakpoint within this gene, we generated a pool of long-polymerase chain reaction (PCR) products (TN2-TN7) spanning the genomic region from intron 3 to intron 12 (chr3: 172 344 335-172 417 421; Figure 1a and b; the pairs of primers used to obtain the LONG-PCR fragments are listed in Table 1 ). The probe pool detected, in addition to a signal on the normal chromosome 3, two splitting signals on der(3) and der(12), thus indicating that the breakpoint was located inside TNIK (Figure 1a and b) . A LONG-PCR experiment using a forward primer specific for exon 5 of the HMGA2 gene (Ex5aF , Table 1 ) and the reverse primer TNIK4R from the TNIK gene (Table 1) , designed to amplify the junction region on der(12), generated a fragment of B8.5 kb (data not shown). Nested PCR experiments with the primer combination Ex5aF and TNIK4.1R (6757 bp centromeric to TNIK4R, Table 1 ) yielded a PCR product of 1780 bp. Both PCR experiments failed to produce any amplification fragment in control experiments using the DNA from a healthy individual (Figure 1c ). The 1780 bp fragment was entirely sequenced. Sequence analysis showed that chromosome 12, at nucleotide (nt) 64 644 064 (exon 5 of HMGA2), was fused with chromosome 3 at nt 172 374 322 (intron 9 of TNIK) ( Figure 1d ). The reciprocal genomic junction TNIK/HMGA2 was also PCR amplified using the primer set TNIK2BR.F/EX5aR. The resulting 1130 bp fragment ( Figure 1c ) was sequenced. It revealed that chromosome 3, at nt 172 374 440 (intron 9 of TNIK), was fused with chromosome 12 at nt 64 643 497 (exon 5 of HMGA2) ( Figure 1e ). Sequence comparison of the two breakpoint regions, using the BLAT tool of the UCSC Genome Browser, revealed the occurrence of 118 and 567 bp nucleotide overlaps, respectively, within TNIK intron 9 and HMGA2 exon 5 (data not shown). Moreover, nucleotide microhomologies of two nucleotides (AG) and six nucleotides (ATCACAT) were detected at the translocation junctions, respectively, on chromosomes der(12) and der(3) (Figure 1d and e). Although the two genes appeared fused at the genomic level, 3 0 rapid amplification of cloned ends (RACE)-PCR (Clontech/BD Biosciences, Mountain View, CA, USA) experiments excluded the presence of a 5 0 HMGA2/3 0 TNIK chimeric transcript (data not shown).
The HMGA2 and TNIK gene expression level was determined by real-time PCR using 1 Â Platinum s SYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA). The gene expression level variation was estimated by comparing the values of 2
ÀDDCt (relative amount of cDNA) for both the HMGA2 and TNIK genes' C t values in the patient with t(3;12) with the relative value of a control, obtained considering a C t mean value. The significance was estimated by comparing respective ranges ð2
ÀDDCt AE s:d:Þ of these values (Figure 1f and g ). 28S rRNA was used as reference gene and one (No. 6, Figure 1f and g) of the six PV cases with a normal karyotype (controls), included in the study, was utilized as calibrator. Real-time PCR analyses of the HMGA2 and TNIK expression levels revealed upregulation of both HMGA2 exon 3 and exon 5 (Figure 1f ), but no noteworthy changes in the expression level of TNIK (Figure 1g) were detected. For the latter gene, we used primers specific for regions both upstream (exons 2-3, 8-9) and downstream (exons 10, 11-12, 17-18) of the breakpoint (primer sequences are available on request).
In summary, our study have indicated that the HMGA2 full transcript (exons 1-5) level was higher in the patient bearing the t(3;12) translocation than in other PV cases with a normal karyotype (Figure 1f ). The upregulation of HMGA2 was likely due to a position effect. This phenomenon has already been documented, by our and other groups, in hematological disorders involving the EVI1 gene. 3 In fact, the breakpoint, at the genomic level, was mapped within the 3 0 UTR of the gene, a region containing regulatory elements that exert posttranscriptional expression control. 4 It can be, therefore, hypothesized that the removal of this gene segment alters the expression pattern of HMGA2 by upregulation of the 'wild-type' transcript (HMGA2a) rather than by switching towards cryptic or aberrant splicing products. HMGA2 encodes a protein that belongs to the non-histone chromosomal high-mobility group protein A family (HMGA). These phosphoproteins are characterized by three AT hook motifs interacting with the minor groove of AT-rich DNA sequences. By orchestrating multiple protein-protein and protein-DNA interactions, HMGA proteins actively participate in a wide variety of nuclear activities, including DNA replication, DNA repair, chromatin remodeling, control of gene transcription, and regulation of mRNA processing. 5 This gene has an important role in cancer, as it is thought to contribute to the transformation process, either through its overexpression or through the formation of fusion genes, as in a variety of human mesenchymal tumors, or, additionally, through an aberrant splicing leading to HMGA2 truncated transcripts composed of exons 1-3 and an alternative terminal exon within intron 3. 5 Chromosomal rearrangements involving HMGA2 have been described only in few cases of hematological malignancies. In some of them, the partner gene in translocation (or inversion) was identified, although 3 0 RACE-PCR analysis excluded the possibility of a fusion transcript. 6, 7 In some of them, aberrant truncated forms of HMGA2 transcripts were described as containing exons 1-3 and a sequence from intron 3 or intron 2, 7 leading to truncation of the acidic carboxyl domain of the protein. 6, 7 HMGA2 activation has been reported in myelodysplasia 7 and myelofibrosis with myeloid metaplasia, Letters to the Editor with both Traf2 and NCK, and able to specifically activate the Jun N-terminal kinase domain pathway. 8 In conclusion, we hypothesize that, following the t(3;12) rearrangement, the translocation of the promoter and the 5 0 portion of TNIK downstream to HMGA2 leads to the activation of the latter gene as a consequence of a position effect. 
